Lonza launches 4D-Nucleofector LV Unit for large-scale transfection

Lonza has announced the launch of its new 4D-Nucleofector LV Unit, the latest addition to its transfection platform offering.

The new unit expands the proven capabilities of the 4D-Nucleofector System to provide closed larger-scale transfection. Protocols can be established at a smaller scale using the 4D-Nucleofector X Unit and smoothly scaled up without the need for re-optimisation.

Lonza's Nucleofector Technology is an improved electroporation technique that delivers high efficiencies that can be achieved using much lower amounts of substrate, with only a moderate impact on viability. It was originally launched in 2001.

Transfection is a technique used to study and control gene expression by delivering DNA, RNA and proteins into cells, for applications such as cell modification, the production of transient proteins or antibodies for construct screening, and the generation of disease models via genome editing for cell-based assays.

Herbert Mueller-Hartmann, head of research and technology at Lonza, said: "The new addition of a larger-scale transfection format allows us to accompany scientists as they translate the results of their research applications into potential therapeutic applications."

The firm also announced this week that it will continue to support horseshoe crab conservation initiatives by the Ecological Research and Development Group through 2016, recognising the essential role these animals play in pharmaceutical research.